

# Proteomics reveals antiviral host response and NETosis during acute COVID-19 in high-risk patients

Alina Bauer<sup>1\*</sup>, Elisabeth Pachtl<sup>1,2\*</sup>, Johannes C. Hellmuth<sup>3,4,5\*</sup>, Nikolaus Kneidinger<sup>6,7</sup>, Motaharehsadat Heydari<sup>6</sup>, Marion Frankenberger<sup>6</sup>, Hans C. Stubbe<sup>5,8</sup>, Bernhard Ryffel<sup>9</sup>, Agnese Petrera<sup>10</sup>, Stefanie M. Hauck<sup>10</sup>, Jürgen Behr<sup>6,7</sup>, Rainer Kaiser<sup>5,11</sup>, Clemens Scherer<sup>5,11</sup>, Li Deng<sup>1,12</sup>, Daniel Teupser<sup>13</sup>, Narges Ahmidi<sup>2</sup>, Maximilian Muenchhoff<sup>5,14,15\*</sup>, Benjamin Schubert<sup>1,16\*</sup>, Anne Hilgendorff<sup>6,17+\*</sup>

\* These authors contributed equally to this work.

+ Corresponding Author: [anne.hilgendorff@med.uni-muenchen.de](mailto:anne.hilgendorff@med.uni-muenchen.de)

<sup>1</sup>Helmholtz Zentrum München, Computational Health Department, Member of the German Center for Lung Research (DZL), 85764 Munich, Germany

<sup>2</sup>Fraunhofer IKS, Fraunhofer Institute for Cognitive Systems IKS, 80686 Munich, Germany

<sup>3</sup>Department of Medicine III, University Hospital, LMU Munich, Munich, Germany

<sup>4</sup>German Cancer Consortium (DKTK), Munich, Germany

<sup>5</sup>COVID-19 Registry of the LMU Munich (CORKUM), University Hospital, LMU Munich, Munich, Germany

<sup>6</sup>Institute of Lung Biology and Disease and Comprehensive Pneumology Center with the CPC-M bioArchive, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany

<sup>7</sup>Department of Medicine V, University Hospital, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany

<sup>8</sup>Department of Medicine II, University Hospital, LMU Munich, Munich, Germany

<sup>9</sup>Laboratory of Experimental and Molecular Immunology and Neurogenetics (INEM), UMR 7355 CNRS-University of Orleans and Artimmune, Orléans, France

<sup>10</sup>Metabolomics and Proteomics Core, Helmholtz Zentrum München, Munich, Germany

<sup>11</sup>Medizinische Klinik und Poliklinik I, University Hospital, LMU Munich, Munich, Germany, DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany

<sup>12</sup>Institute of Virology, Technical University of Munich, 81675 Munich, Germany

<sup>13</sup>Institute of Laboratory Medicine, University Hospital, LMU Munich, Munich, Germany

<sup>14</sup>Max von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, LMU München, Munich, Germany

<sup>15</sup>German Center for Infection Research (DZIF), partner site Munich, Munich, Germany

<sup>16</sup>Department of Mathematics, Technical University of Munich, 85748 Garching bei München, Germany

<sup>17</sup>Center for Comprehensive Developmental Care (CDeC<sup>LMU</sup>) at the interdisciplinary Social Pediatric Center (iSPZ), LMU Hospital, Munich, Germany

## Corresponding Author:

Anne Hilgendorff, Dr. med habil

Institute for Lung Biology and Disease and Comprehensive Pneumology Center Helmholtz Center Munich

Center for Comprehensive Developmental Care, University Hospital Ludwig-Maximilian University, Munich, Germany

[A.Hilgendorff@med.uni-muenchen.de](mailto:A.Hilgendorff@med.uni-muenchen.de)

## **Supplementary Tables**

Table S1: Description of confounders

Table S2: Clinical characteristics for different subgroups of the cohort at admission

Table S3: Results of subgroup comparisons for clinical characteristics and biomedical indices at admission

Table S4: Details of statistical analysis of clinical parameters

Table S5: Reference values for routine biochemical indices

Table S6: Routine biochemical indices for disease phase assignment

Table S7: Log<sub>2</sub>(fold change) of routine biochemical indices for groupwise comparisons

Table S8: Differential Abundance Analysis Results in the Study Cohort: Phases compared to control groups

Table S9: Pathway Enrichment Analysis in the Study Cohort: Phases compared to control groups

Table S10: Differential Abundance Analysis Results in the Validation Cohort: Phases compared to control groups


Table S11: Differential Abundance Analysis Results in the Study Cohort: Trajectory comparisons



Table S12: Pathway Enrichment Analysis Results in the Study Cohort: Trajectory comparisons



# Supplementary Figures



## Figure S1: Individual patient trajectories of CRP and IL-6.

Covid-positive: max WHO score =1 (n= 8)















Covid-positive: max WHO score =2 (n= 4)















Covid-positive: max WHO score =3 (n= 25)
















































Patient:37  
WHO Score max:3



Covid-positive: max WHO score =4 (n= 10)













Patient:44  
WHO Score max:4





Patient:45  
WHO Score max:4








Covid-positive: max WHO score =5 (n= 2)




Covid-positive: max WHO score =6 (n= 8)







Patient:52  
WHO Score max:6



Patient:53  
WHO Score max:6













Covid-positive: max WHO score =7 (n= 0)

Covid-positive: max WHO score =8 (n= 7)













Patient:64  
WHO Score max:8




# Covid-negative (n= 19)




Patient:67  
WHO Score max:0




Patient:68  
WHO Score max:0




Patient:69  
WHO Score max:0




Patient:70  
WHO Score max:0





Patient:71  
WHO Score max:0




Patient:72  
WHO Score max:0









Patient:75  
WHO Score max:0




Patient:76  
WHO Score max:0





Patient:77  
WHO Score max:0




Patient:78  
WHO Score max:0







Patient:81  
WHO Score max:0






Patient:82  
WHO Score max:0





Patient:83  
WHO Score max:0



















Patient:M418tri




Patient:M212cbm










Patient:M490siv







Patient:M455rol


















































Figure S2: Time between nearest laboratory sample and protein sample. Color Code for the mean difference in days is shown on the right. The respective standard deviation for every laboratory value for the available information is shown as a number in every cell.




Figure S3: Missing laboratory values during disease trajectory




Figure S4: Severity-based trajectory of routine biochemical indices




Figure S5: Pathway enrichment analysis for trajectory-based (*acute-early*, *acute-late*, *recovery phase*) comparison to both control groups (*Ctrl-infl*, *Ctrl-noninfl*)



Figure S6: Volcano plot of all phase comparisons and severity-based phase




Figure S7: Distribution of chosen differential abundant proteins for disease trajectory.

